Public Health Emergency - Leading a Nation Prepared
Monoclonal antibody treatments have been shown to reduce hospitalization and symptom days in high-risk COVID-19 patients with mild to moderate symptoms. Your eligible patients who have had mild to moderate symptoms for 10 days or less may benefit from treatment with certain monoclonal antibody drugs.
Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful antigens, such as viruses. Monoclonal antibodies to treat COVID-19 target the spike protein of SARS-COV2, to block the virus’ attachment and entry into human cells.
Two COVID-19 monoclonal antibody therapeutics, casirivimab/imdevimab and bamlanivimab/etesevimab have been granted Emergency Use Authorization (EUA) from the FDA for the treatment of eligible COVID-19 patients.
Patients who meet the following criteria or demonstrate the following symptoms may be eligible to receive COVID-19 monoclonal antibody therapeutics:
Patients who receive a COVID-19 vaccine and subsequently develop related infection may receive monoclonal antibody therapy.
Mild symptoms may include fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, and loss of taste and smell. Moderate symptoms may also include shortness of breath.
Patients who have been hospitalized are not eligible to receive COVID-19 monoclonal antibody treatments because the treatment has not been shown to benefit hospitalized patients.
Only high-risk groups have been authorized for treatment at this time. High-risk individuals include:
Monoclonal antibodies should only be administered in settings where health care providers have immediate access to medications to treat severe infusion reaction, such as anaphylaxis, and the ability to activate the emergency medical system, if necessary. Required elements for administering monoclonal treatment can be found in the Emergency Use Authorization and in the resources section below.
To find potential locations for treatment with monoclonal antibody therapeutics, HHS offers a web-based COVID-19 outpatient
treatment locator. Additional information on sites in your area may be found on the
NICA Infusion Center Tool. Currently, treatments are available at
thousands of locations across the country.
To get more information about monoclonal antibody treatments or identify an infusion site near you call the mAb call center:
English: 1-877-332-6585Spanish: 1-877-366-0310
Additional treatment options can be found on the
Home | Contact Us | Accessibility | Privacy Policies | Disclaimer | HHS Viewers & Players | HHS Plain Language
Assistant Secretary for Preparedness and Response (ASPR), 200 Independence Ave., SW, Washington, DC 20201
U.S. Department of Health and Human Services | USA.gov |
HealthCare.gov in Other Languages